Details of the Drug

General Information of Drug (ID: DMJL09Z)

Drug Name

Aficamten

Synonyms

Aficamten; 2364554-48-1; Aficamten [INN]; Aficamten [USAN]; CK-3773274; B1I77MH6K1; Aficamten [USAN:INN]; UNII-B1I77MH6K1; CHEMBL4847050; WHO 11544; 1H-Pyrazole-4-carboxamide, N-((1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-; N-((1R)-5-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide; N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide; SCHEMBL21179170; GTPL11524; EX-A5344; BDBM50575173; CK-274; AKOS040759755; MS-25122; CK3773274; HY-139465; CK-3773274;CK-274; CS-0202223; (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Hypertrophic cardiomyopathy	BC43.1	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C18H19N5O2
Canonical SMILES: CCC1=NC(=NO1)C2=CC3=C(C=C2)C(CC3)NC(=O)C4=CN(N=C4)C
InChI: InChI=1S/C18H19N5O2/c1-3-16-21-17(22-25-16)12-4-6-14-11(8-12)5-7-15(14)20-18(24)13-9-19-23(2)10-13/h4,6,8-10,15H,3,5,7H2,1-2H3,(H,20,24)/t15-/m1/s1
InChIKey: IOVAZWDIRCRMTM-OAHLLOKOSA-N

Cross-matching ID

PubChem CID: 139331495
TTD ID: D6SY9X

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cardiac myosin (MYBPC3)	TT9WOBN	MYPC3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05767346) A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. U.S.National Institutes of Health.
2	Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142-14152.